The abstract is read at the publisher; the summary is JClub's.
MAP1A is significantly upregulated in triple-negative breast cancer patients with anti-PD-1 resistance and promotes an immunologically cold tumor state that resists anti-PD-1 therapy in murine models.
- Why it matters: Primary resistance to immune checkpoint inhibitors limits durable benefit in TNBC, and the mechanisms linking tumor programs to anti-PD-1 failure remain unclear.
- What they did: The study integrated transcriptomic profiles with immunotherapy clinical response data to nominate resistance regulators, then tested MAP1A using in vitro and in vivo syngeneic mouse models plus RNA sequencing, flow cytometry, co-immunoprecipitation, and protein stability assays.
- The result: MAP1A interacted with JAK1 to regulate its ubiquitination and degradation, suppressing STAT1 phosphorylation and MHC-I/antigen presentation machinery gene transcription; inhibiting TGF-β signaling with galunisertib enhanced MHC-I-related programs and sensitized MAP1A-high tumors to anti-PD-1 in vivo.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.